• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

    1/29/24 4:00:59 PM ET
    $SLGC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SLGC alert in real time by email
    SC 13G/A 1 tm244117d33_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

    SomaLogic, Inc.

    (Name of Issuer)

     

    Common stock

    (Title of Class of Securities)

     

    83444K105

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)

    ¨  Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 83444K105 13G Page 2 of 5 Pages 

     

    1. NAMES OF REPORTING PERSONS  
    ARK Investment Management LLC  
     
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
    (a) ¨  
    (b) ¨  
    3. SEC USE ONLY  
       
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
    Delaware, United States  
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER  
    14,241,979      
     
    6. SHARED VOTING POWER  
    0  
     
    7. SOLE DISPOSITIVE POWER  
    14,241,979  
     
    8. SHARED DISPOSITIVE POWER  
    0  
     
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
    14,241,979  
     
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
    ¨  
     
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
    7.55%  
     
    12. TYPE OF REPORTING PERSON  
    IA  
     

     

     

     

     

    CUSIP No. 83444K105 13G Page 3 of 5 Pages 

     

    Item 1(a) Name of issuer:            

     

    SomaLogic, Inc.

      

    Item 1(b) Address of issuer's principal executive offices:            

     

    2945 Wilderness Place

    Boulder, CO 80301

     

    Item 2(a) Name of person filing:            

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    200 Central Avenue

    St. Petersburg, FL 33701

     

    Item 2(c) Citizenship:         

     

    Delaware, United States 

     

    Item 2(d) Title of class of securities:             

     

    Common stock

     

    Item 2(e) CUSIP No.:

     

    83444K105

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

    CUSIP No. 83444K105 13G Page 4 of 5 Pages 

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4. Ownership          

     

    (a)Amount beneficially owned:

     

    14,241,979

     

    (b)Percent of class:

     

    7.55%

     

    (c)Number of shares as to which such person has:

     

    (i)  Sole power to vote or to direct the vote:  14,241,979

     

    (ii) Shared power to vote or to direct the vote:  0

     

    (iii) Sole power to dispose or to direct the disposition of:  14,241,979

     

    (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

      

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    CUSIP No. 83444K105 13G Page 5 of 5 Pages 

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

    Dated:    January 29, 2024

     

      ARK Investment Management LLC  
         
      By: /s/ Kellen Carter
        Name:  Kellen Carter
        Title:    Chief Compliance Officer

     

     

    Get the next $SLGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGC

    DatePrice TargetRatingAnalyst
    10/5/2023$3.50 → $2.29Buy → Hold
    Jefferies
    9/25/2023$5.00 → $2.50Buy → Hold
    Canaccord Genuity
    2/1/2022$12.00Buy
    Stifel
    12/14/2021$19.00Buy
    Canaccord Genuity
    12/10/2021$16.00Buy
    Jefferies
    11/23/2021$18.00Outperform
    Cowen & Co.
    More analyst ratings

    $SLGC
    SEC Filings

    See more
    • SEC Form 15-12G filed by SomaLogic Inc.

      15-12G - SomaLogic, Inc. (0001837412) (Filer)

      1/16/24 8:00:29 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by SomaLogic Inc.

      EFFECT - SomaLogic, Inc. (0001837412) (Filer)

      1/12/24 12:15:06 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by SomaLogic Inc.

      EFFECT - SomaLogic, Inc. (0001837412) (Filer)

      1/12/24 12:15:08 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SomaLogic downgraded by Jefferies with a new price target

      Jefferies downgraded SomaLogic from Buy to Hold and set a new price target of $2.30 from $3.50 previously

      10/5/23 7:49:23 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded SomaLogic from Buy to Hold and set a new price target of $2.50 from $5.00 previously

      9/25/23 9:02:13 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Stifel initiated coverage on SomaLogic with a new price target

      Stifel initiated coverage of SomaLogic with a rating of Buy and set a new price target of $12.00

      2/1/22 6:15:39 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024

      Data to showcase PROphet® platform's machine learning models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024. The oral presentation will feature insights from the company's PROPHETIC trial, to be delivered by Prof. Jarushka Naidoo, consultant medical oncologi

      3/5/24 4:35:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Standard BioTools Stockholders Approve Merger with SomaLogic

      SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (NASDAQ:SLGC) at its Special Meeting of Stockholders. "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support for this merger," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Together with SomaLogic, we will have an expanded platform to better serve our customers and we be

      1/4/24 10:23:06 PM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

      Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo., Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools"). The SomaLogic Board of Directors issued the following statement: We are grateful for the suppor

      1/4/24 9:44:00 PM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

      SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)

      1/29/24 5:25:49 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

      SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)

      1/29/24 4:00:59 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by SomaLogic Inc. (Amendment)

      SC 13D/A - SomaLogic, Inc. (0001837412) (Subject)

      1/9/24 5:16:22 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SomaLogic Announces Chief Financial Officer Transition

      Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti

      6/6/23 4:05:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

      BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022. Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board. Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 bill

      10/17/22 4:30:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:54:27 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Ryan Jason

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:53:22 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:52:15 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Financials

    Live finance-specific insights

    See more
    • SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders

      Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders reiterating the Board's belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders. The full text of the letter is as follows: Dear Fellow Stockholders, We firmly believe that the value-maximizing transaction with Standard BioTools is the best path forward for SomaLogic and all of its stockhold

      12/29/23 8:42:00 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ISS Recommends SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools

      BOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services ("ISS") has recommended that SomaLogic stockholders vote "FOR" the pending merger with Standard BioTools at the company's Special Meeting of Stockholders to be held on January 4, 2024. In its "FOR" recommendation to SomaLogic stockholders, ISS noted1: The strategic rationale of combining two sub-scale companies in order to slow down cash burn and accelerate the path to profitability appears reasonable, particularly given the apparent overlap in the two companies' offerings and the estimated synergies in this transaction.…the all-sto

      12/22/23 6:47:52 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

      Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn's Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential Benefits of the Merger Urges Stockholders to Vote "FOR" Merger Ahead of Special Meeting of Stockholders on January 4, 2024 BOULDER, Colo., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC) today issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools (NASDAQ:LAB) on October 4, 2023. The Company also filed an investor presentation, which can be found on th

      12/21/23 8:00:00 AM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care